Journal of Pharmacogenomics & Pharmacoproteomics

Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin

A pharmacometabonomic approach to predicting metabolic phenotypes and pharmacokinetic parameters of atorvastatin in healthy volunteers

SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders

Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions

Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer's disease and related risk factors

Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease

Gene interactions in the pharmacogenomics of Alzheimer's disease

Can cloud-based tools accelerate Alzheimer's disease drug discovery?

Pharmacogenetics of vascular risk factors in Alzheimer's disease

Genetic variants specific to aging-related verbal memory: Insights from GWASs in a population-based cohort

Pharmacogenomics of Alzheimer's and Parkinson's diseases

Opportunities in pharmacogenomics for the treatment of Alzheimer's disease

Sirtuins in alzheimer's disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics

The role of pharmacogenomics in adverse drug reactions

Pharmacogenetic considerations in the treatment of Alzheimer's disease

The broad impact of TOM40 on neurodegenerative diseases in aging

Spectrum of neuromuscular disorders with hyperCKemia from a tertiary care pediatric neuromuscular center

Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia

Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum